Auditing by the Numbers - Contract organizations must have highly organized teams and plans to accommodate today's audits. - BioPharm International

ADVERTISEMENT

Auditing by the Numbers
Contract organizations must have highly organized teams and plans to accommodate today's audits.


BioPharm International
Volume 25, Issue 1, pp. 22-23

Because contract organizations also must perform internal audits, which typically last one week and occur once a quarter, the numbers above equate to approximately 26 weeks or half of a year devoted to handling and conducting audits. This amount of time does not take into account preparation of responses to any potential audit observations or necessary follow-up activities.

To successfully accommodate all of these audits, a contract organization must maintain a full-time contingent. Organizations must be aware that the time commitment entails more than preparing and hosting audit groups. Each audit could easily take 4 to 5 weeks when considering preparation, hosting functions (both escorting and staging room activities), responses, and followup.

In addition, the organization must have a unique layer of resources to manage internal cGMP audit programs, which are required by regulators to ensure that each facility has a process for meeting compliance. Typically, these resources are passed on to customers as part of the cost for a contracted operation.

Given these expectations, there seems to be an opportunity for industry to work with consortiums such as Rx–360 or the International Pharmaceutical Excipients Auditing (IPEA) program to share audits and thereby ease overall costs and time tied to the audits. Moving in the direction of shared audits, however, requires more consistent interpretations and expectations, general acceptance of responses, and perhaps a certification process.

Companies using contract services must be willing to share their audit programs and compromise on what should be the ideal approach to assessing GMP compliance of contract organizations. They must agree to a set of criterion to be consistently applied for auditing and they must be somewhat consistent in their interpretation of the regulations. This would allow contract organizations to be able to maintain a robust quality system that is suitable for multiple clients. The use of shared audits has been discussed for quite a while and it seems that Rx–360 and IPEA have started down the road of solving the problem for raw-material suppliers. Let's hope they agree to continue with the process and help out contract organizations in the same manner.

Susan J. Schniepp is vice-president of quality at OSO Biopharmaceuticals,
.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here